1. any vaccination/immunization within 30 days before the enrolment 2. steroids (except hormonal contraceptives) and immunoglobulins or other blood products therapy not finished 30 days before the enrolment 3. immunosuppressors therapy finished within 3 months before the enrolment 4. pregnancy or breast-feeding 5. acute coronary syndrome or stroke suffered less than one year before the enrolment 6. tuberculosis, chronic systemic infections 7. drug allergy (anaphylactic shock, quincke edema, polymorphic exudative eczema, atopy, serum disease),hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study product components, acute exacerbation of allergic diseases on the enrolment day 8. subjects who are on drugs that could have potential drug interactions with adenovirus vaccine 9. medical history of malignancy 10. donated blood or plasma (450+ ml) within 2 months before the enrolment 11. splenectomy in the medical history 12. neutropenia (absolute neutrophil count less than 1,000 mm3), agranulocytosis, significant blood loss,severe anaemia (haemoglobin less than 80 g/l), immunodeficiency including autoimmune disorders in the medical history within 6 months before the enrolment 13. active form of a disease caused by the hiv and hepatitis b or c 14. anorexia, protein deficiency of any origin 15. tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the imp or placebo administration 16. alcohol or drug addiction in the medical history. 17. participation in any other interventional clinical trial within 1 month prior to the screening 18. any other medical condition that would limit the participation of the subject as per investigator discretion 19. study centre staff or other employees directly involved in the trial and their families 20. subjects contraindicated for vaccination

1. any vaccination/immunization within 30 days before the enrolment 2. steroids (except hormonal contraceptives) and immunoglobulins or other blood products therapy not finished 30 days before the enrolment 3. immunosuppressors therapy finished within 3 months before the enrolment 4. pregnancy or breast-feeding 5. acute coronary syndrome or stroke suffered less than one year before the enrolment 6. tuberculosis, chronic systemic infections 7. drug allergy (anaphylactic shock, quincke edema, polymorphic exudative eczema, atopy, serum disease),hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study product components, acute exacerbation of allergic diseases on the enrolment day 8. subjects who are on drugs that could have potential drug interactions with adenovirus vaccine 9. medical history of malignancy 10. donated blood or plasma (450+ ml) within 2 months before the enrolment 11. splenectomy in the medical history 12. neutropenia (absolute neutrophil count less than 1,000 mm3), agranulocytosis, significant blood loss,severe anaemia (haemoglobin less than 80 g/l), immunodeficiency including autoimmune disorders in the medical history within 6 months before the enrolment 13. active form of a disease caused by the hiv and hepatitis b or c 14. anorexia, protein deficiency of any origin 15. tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the imp or placebo administration 16. alcohol or drug addiction in the medical history. 17. participation in any other interventional clinical trial within 1 month prior to the screening 18. any other medical condition that would limit the participation of the subject as per investigator discretion 19. study centre staff or other employees directly involved in the trial and their families 20. subjects contraindicated for vaccination

any vaccination/immunization within 30 days before the enrolment steroids (except hormonal contraceptives) and immunoglobulins or other blood products therapy not finished 30 days before the enrolment immunosuppressors therapy finished within 3 months before the enrolment pregnancy or breast-feeding acute coronary syndrome or stroke suffered less than one year before the enrolment tuberculosis, chronic systemic infections drug allergy (anaphylactic shock, quincke edema, polymorphic exudative eczema, atopy, serum disease),hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study product components, acute exacerbation of allergic diseases on the enrolment day subjects who are on drugs that could have potential drug interactions with adenovirus vaccine medical history of malignancy donated blood or plasma (450+ ml) within 2 months before the enrolment splenectomy in the medical history neutropenia (absolute neutrophil count less than 1,000 mm3), agranulocytosis, significant blood loss,severe anaemia (haemoglobin less than 80 g/l), immunodeficiency including autoimmune disorders in the medical history within 6 months before the enrolment active form of a disease caused by the hiv and hepatitis b or c anorexia, protein deficiency of any origin tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the imp or placebo administration alcohol or drug addiction in the medical history. participation in any other interventional clinical trial within 1 month prior to the screening any other medical condition that would limit the participation of the subject as per investigator discretion study centre staff or other employees directly involved in the trial and their families subjects contraindicated for vaccination

any vaccination/immunization within 30 days before the enrolment steroids (except hormonal contraceptives) and immunoglobulins or other blood products therapy not finished 30 days before the enrolment immunosuppressors therapy finished within 3 months before the enrolment pregnancy or breast-feeding acute coronary syndrome or stroke suffered less than one year before the enrolment tuberculosis, chronic systemic infections drug allergy (anaphylactic shock, quincke edema, polymorphic exudative eczema, atopy, serum disease),hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study product components, acute exacerbation of allergic diseases on the enrolment day subjects who are on drugs that could have potential drug interactions with adenovirus vaccine medical history of malignancy donated blood or plasma (450+ ml) within 2 months before the enrolment splenectomy in the medical history neutropenia (absolute neutrophil count less than 1,000 mm3), agranulocytosis, significant blood loss,severe anaemia (haemoglobin less than 80 g/l), immunodeficiency including autoimmune disorders in the medical history within 6 months before the enrolment active form of a disease caused by the hiv and hepatitis b or c anorexia, protein deficiency of any origin tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the imp or placebo administration alcohol or drug addiction in the medical history. participation in any other interventional clinical trial within 1 month prior to the screening any other medical condition that would limit the participation of the subject as per investigator discretion study centre staff or other employees directly involved in the trial and their families subjects contraindicated for vaccination

1. any vaccination/immunization within 30 days before the enrolment 2. steroids (except hormonal contraceptives) and immunoglobulins or other blood products therapy not finished 30 days before the enrolment 3. immunosuppressors therapy finished within 3 months before the enrolment 4. pregnancy or breast-feeding 5. acute coronary syndrome or stroke suffered less than one year before the enrolment 6. tuberculosis, chronic systemic infections 7. drug allergy (anaphylactic shock, quincke edema, polymorphic exudative eczema, atopy, serum disease),hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study product components, acute exacerbation of allergic diseases on the enrolment day 8. subjects who are on drugs that could have potential drug interactions with adenovirus vaccine 9. medical history of malignancy 10. donated blood or plasma (450+ ml) within 2 months before the enrolment 11. splenectomy in the medical history 12. neutropenia (absolute neutrophil count less than 1,000 mm3), agranulocytosis, significant blood loss,severe anaemia (haemoglobin less than 80 g/l), immunodeficiency including autoimmune disorders in the medical history within 6 months before the enrolment 13. active form of a disease caused by the hiv and hepatitis b or c 14. anorexia, protein deficiency of any origin 15. tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the imp or placebo administration 16. alcohol or drug addiction in the medical history. 17. participation in any other interventional clinical trial within 1 month prior to the screening 18. any other medical condition that would limit the participation of the subject as per investigator discretion 19. study centre staff or other employees directly involved in the trial and their families 20. subjects contraindicated for vaccination

1. any vaccination/immunization within 30 days before the enrolment 2. steroids (except hormonal contraceptives) and immunoglobulins or other blood products therapy not finished 30 days before the enrolment 3. immunosuppressors therapy finished within 3 months before the enrolment 4. pregnancy or breast-feeding 5. acute coronary syndrome or stroke suffered less than one year before the enrolment 6. tuberculosis, chronic systemic infections 7. drug allergy (anaphylactic shock, quincke edema, polymorphic exudative eczema, atopy, serum disease),hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study product components, acute exacerbation of allergic diseases on the enrolment day 8. subjects who are on drugs that could have potential drug interactions with adenovirus vaccine 9. medical history of malignancy 10. donated blood or plasma (450+ ml) within 2 months before the enrolment 11. splenectomy in the medical history 12. neutropenia (absolute neutrophil count less than 1,000 mm3), agranulocytosis, significant blood loss,severe anaemia (haemoglobin less than 80 g/l), immunodeficiency including autoimmune disorders in the medical history within 6 months before the enrolment 13. active form of a disease caused by the hiv and hepatitis b or c 14. anorexia, protein deficiency of any origin 15. tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the imp or placebo administration 16. alcohol or drug addiction in the medical history. 17. participation in any other interventional clinical trial within 1 month prior to the screening 18. any other medical condition that would limit the participation of the subject as per investigator discretion 19. study centre staff or other employees directly involved in the trial and their families 20. subjects contraindicated for vaccination